Castle Biosciences, Inc. (NASDAQ:CSTL) stock soared 5.53% in after-hours trading on November 4th after the company reported impressive third quarter 2024 financial results that handily beat Wall Street expectations.
For the quarter ended September 30, 2024, the company reported earnings per share (EPS) of $0.08, significantly higher than the consensus analyst estimate of -$0.03. Castle Biosciences' revenue came in at $85.8 million, up 39.53% year-over-year and surpassing the $79.842 million estimate by 7.46%.
The strong earnings beat and robust revenue growth underscored the continued strength of Castle Biosciences' business and its ability to drive profitability. Investors cheered the exceptional results, bidding the stock higher in extended trading as the company demonstrated its ability to exceed lofty expectations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.